Immunopotentiators in Modern Vaccines

Dr. Virgil E.J.C. Schijns is special guest Professor in Cell Biology & Immunology group, Wageningen University, 6708 WD Wageningen, The Netherlands. Dr. Schijns received his PhD degree at Utrecht University in 1990. Recent professional appointments are Chief Scientific Officer at ERC in Belgium and The Netherlands, (2011 to present); Chief Technology Officer, Vice President at a small biotech spin-off from Utrecht University (2008 to 2011); Special Professor, Immune Intervention, Wageningen University and Research Center (2008 to present); Special Professor in Immunology and Virology at North Carolina State University (NCSU), Raleigh. Department of Population Health and Pathobiology (2002 to present) and Head of Department for Vaccine Technology and Immunology (VTI), AKZO NOBEL (1999 to 2008).Dr. Derek T. O’Hagan is a formulation scientist and vaccine adjuvant expert with extensive industry experience. He served as Global Head of Vaccine Chemistry and Formulation Research at Novartis Vaccines before its acquisition by GSK. With a background in pharmacy from the UK, he has worked in vaccine delivery research since 1993, including academic roles at the University of Nottingham. Dr. O’Hagan has led research on adjuvants such as MF59, now licensed in flu vaccines in over 40 countries. He has authored over 140 research publications, 60+ patents, and numerous book chapters. Recognized for innovation, he received the Royal Pharmaceutical Society’s Conference Science Medal and the Controlled Release Society’s Young Investigator Award. His work focuses on adjuvant development, nucleic acid vaccines, and needle-free delivery systems, making him a leading figure in vaccine formulation science.

• 1. Vaccine Adjuvants' Mode of Action: Unraveling ‘‘the Immunologist's Dirty Little Secret”2. The Role of Inflammasomes in Adjuvant-Driven Humoral and Cellular Immune Responses3. Dendritic Cells as Targets of Vaccines and Adjuvants4. Host-Derived Cytokines and Chemokines as Vaccine Adjuvants5. Discovery of Immune Potentiators as Vaccine Adjuvants6. Current Status of Toll-Like Receptor 4 Ligand Vaccine Adjuvants7. Flagellins as Adjuvants of Vaccines8. Toll-Like Receptor 7 and 8 Agonists for Vaccine Adjuvant Use9. CpG Oligodeoxynucleotides as Adjuvants for Clinical Use10. Advax Adjuvant: A Potent and Safe Immunopotentiator Composed of Delta Inulin11. Natural Vaccine Adjuvants and Immunopotentiators Derived From Plants, Fungi, Marine Organisms, and Insects12. Polymeric Particles as Vaccine Delivery Systems13. MF59: A Safe and Potent Adjuvant for Human Use14. The Development of the Adjuvant System AS01: A Combination of Two Immunostimulants MPL and QS-21 in Liposomes15. Development and Evaluation of AS04, a Novel and Improved Adjuvant System Containing 3-O-Desacyl-4′- Monophosphoryl Lipid A and Aluminum Salt16. ISCOMATRIX Adjuvant in the Development of Prophylactic and Therapeutic Vaccines17. Development and Evaluation of CAF0118. Mineral Adjuvants19. Toxin-Based Mucosal Adjuvants20. Adjuvants for Skin Vaccination21. Vaccination to Treat Noninfectious Diseases: Surveying the Opportunities22. A Framework for Evaluating Nonclinical Safety of Novel Adjuvants and Adjuvanted Preventive Vaccines